Atyr1923 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 84 | Sarcoidosis | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-004244-33-DE (EUCTR) | 21/10/2019 | 15/07/2019 | A safety study with multiple doses of intravenous (in the vein) ATYR1923 in patients with pulmonary sarcoidosis | A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis | Pulmonary Sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | aTyr Pharma, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 36 | Phase 2 | United States;Germany | |||
| 2 | NCT03824392 (ClinicalTrials.gov) | January 29, 2019 | 28/1/2019 | Study of Intravenous ATYR1923 for Pulmonary Sarcoidosis | A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Biological: ATYR1923 1.0 mg/kg or placebo;Biological: ATYR1923 3.0 mg/kg or placebo;Biological: ATYR1923 5.0 mg/kg or placebo | aTyr Pharma, Inc. | Foundation for Sarcoidosis Research | Recruiting | 18 Years | 70 Years | All | 36 | Phase 1;Phase 2 | United States |